A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 912 participants.

Also called NCT07417306

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 912 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07417306
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07417306. Randomized; no masking; primary purpose treatment. Start 2026-03-27 (anticipated); primary completion 2027-08-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor
Intervention (Drug)
HDM1005 1
Intervention (Drug)
HDM1005 2
Intervention (Drug)
Mazdutide
Lead sponsor
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07417306
Content hash
fbc1d483e0dd510092e90ae831b9c2565364bcbc7e71ec1124021a4d5855734f